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TABLE S1. Pertinent Demographic and Health Information for Study Participants.  
 
 Household Members 
 Parent-1 Parent-2 Sibling-1 Sibling-2 
Age Range (Years) 50-60 50-60 18-25 18-25
Race, Ethnicity White, Non-Hispanic White, Non-Hispanic White, Non-Hispanic White, Non-Hispanic
Self-Described Health Status “Excellent” “Excellent” “Excellent” “Excellent”
Reported Medical Conditions None None None None
 
 
FIGURE S1. Re-analysis of Select Data from Kissler et al. (2020).1 Cycle threshold values from the 
eight individuals who had at least 3 measurements from anterior nares and oropharyngeal (OP) swabs 
during the pre-peak period of infection were converted to viral load and replotted. Viral loads are plotted 
with peak viral load assigned to Day 0. A) Viral load profiles of individuals who became symptomatic 
and B) Viral load profiles of individuals who did not report symptoms. Horizontal blue line on each plot 
depicts the limit of detection (LOD) of Abbott ID NOW (3x105 copies/mL from U.S. FDA SARS-CoV-2 
Reference Panel Comparative testing data).2  Horizontal grey bar depicts the range of LODs for 
commercial antigen tests (1.90x105 copies/mL to 9.33x106 copies/mL; see Table S2).
 
 
FIGURE S2. Human RNase P Ct values and SARS-CoV-2 viral load measurements from RT-qPCR for all household contacts.  
 
TABLE S2. Summary of Reported Limits of Detection (LOD) for Rapid Point of Care SARS-CoV-2 Antigen Tests. Information on limit of 
detection was collected from instructions for use (IFU) and from published literature that reported LOD in units of copies/mL or could be 
unambiguously converted to copies/mL.  
 
Company Product 
Limit of 
Detection 
(copies/mL) 
Reference Explanation 
Quidel Sofia SARS Antigen FIA 
6.0x106 Arnaout et al.3 
Estimated from US FDA Emergency Use Authorization 
Instructions For Use
1.36x106 
Pollack et al.4 
In the US FDA Emergency Use Authorization Instructions For 
Use, the Limit of Detection is reported as Tissue Culture 
Infectious Dose 50 (TCID50). Pollack et al. determine a 
conversion from TCID50 per volume to mass of antigen, and 
mass of antigen per volume to RNA copies per volume.  
BD 
Veritor™ Plus System for 
rapid COVID-19 (SARS-
CoV-2) Test 
8.07x105 
Lumira Dx 
COVID-19 SARS-CoV-2 
Antigen Test 
1.9x105 
Instructions for 
Use5 
Estimated from US FDA Emergency Use Authorization 
Instructions For Use. The Limit of Detection is reported as 
TCID50 per volume. The lot of virus from BEI that was used for 
testing is reported in the IFU, and the certificate of analysis for 
that lot provides conversion from the TCID50 value to RNA 
copies per volume.  
Abbott 
PANBIO™ COVID-19 Ag 
Rapid Test Device 
7.94x105 Albert et al.6 
Albert et al report the results of samples tested by RT-qPCR 
(converted to viral load) and the stated POC antigen test to 
define the Limit of Detection.
3.55x106 
Corman et al.7 
Corman et al. report the results of samples tested by RT-qPCR 
(converted to viral load) and the stated POC antigen test to 
define the Limit of Detection. Two tests with particularly poor 
analytical limit of detection (RapidGEN Biocredit COVID-19 
Ag Test, LOD = 1.58x1010 and Coris Bioconcept COVID 19 Ag 
Respi-Strip, LOD=2.88x107) were excluded from this table as 
not representative. 
Healgen 
Coronavirus Ag Rapid Test 
Cassette (Swab) 
2.34x106 
R-Biopharm 
RIDA QUICK SARS-CoV-2 
Ag 
2.09x106 
Nal-
vonminden 
NADAL COVID19-Ag 9.33x106 
Roche  
SD Biosensor SARS-CoV-2 
Rapid Antigen Test 
6.03x106 
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